Study Title

A Pilot Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 in the Same Group of Primary Prostate Cancer Patients

Study Details

Description:

Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the most widely studied 68Ga-PSMA-11. This pilot study was evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients.

Contacts:

Zhaohui Zhu, MD (Principal Investigator)

13611093752@163.com

86-13611093752

Guochang Wang, MD

guochang1007@163.com

86-18516822732

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468